Novavax (NASDAQ:NVAX) is on the verge of a probable FDA approval of its vaccine to prevent RSV (respiratory syncytial virus) infection in older adults. The company has said that results of its Phase 3 clinical trial named Resolve will be announced by the end of this quarter, which ends September 30th.
The Prevalence and Impacts of RSV
There is currently no vaccine for RSV. As the CDC's website explains, RSV...























